Biohaven Ltd (BHVN)
Biohaven is a clinical-stage biopharmaceutical company focused on therapies for patients with neurological and neuropsychiatric diseases. Co. has obtained drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia, and its research programs, develop therapies with indications in epilepsy, mood disorders, Obsessive-Compulsive Disorder, Spinocerebellar Ataxia, Spinal Muscular Atrophy and pain disorders. Co.'s neuroscience portfolio includes a range of pipeline of drug candidates modulating distinct nervous system targets, including Kv7 ion channels, glutamate receptors, myostatin, and transient receptor potential channels.
BHVN SEC Filing Email Alerts Service
| Company Name: |
Biohaven Ltd |
| Website: |
www.biohaven.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding BHVN: |
28 |
| Total Market Value Held by ETFs: |
$395.64M |
| Total Market Capitalization: |
$3.25B |
| % of Market Cap. Held by ETFs: |
12.18% |
|
|
May 1, 2024 • 9:05 PM Eastern
Strong Buy (3.91 out of 4)
75th percentile
|
|
Free BHVN Email Alerts:
